Literature DB >> 15824093

A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.

Suganthini Krishnan1, Elias K Manavathu, Pranatharthi H Chandrasekar.   

Abstract

OBJECTIVES: To study the in vitro fungicidal activity of voriconazole against hyphae of Aspergillus fumigatus and compare the results with those obtained for the known fungicidal drug amphotericin B.
METHODS: A. fumigatus mycelia were grown on Sabouraud dextrose agar and in peptone yeast extract glucose broth until the cultures reached a mid-logarithmic growth phase. The fungicidal activities of voriconazole and amphotericin B against actively growing hyphae of A. fumigatus were examined by a kill-curve experiment and a fungal cell viability test. For the kill-curve study, the drug-treated hyphae were washed, homogenized and resuspended in 1 mL of sterile water, diluted 10-1000 fold and aliquots of 0.1 mL were spread on Sabouraud dextrose agar and allowed to grow for 48 h at 35 degrees C. The cfu were determined and plotted against drug concentrations for each time of exposure to obtain the kill curve. The viability of drug-treated A. fumigatus hyphae was determined by their ability to reduce tetrazolium compound 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide.
RESULTS: Exposure of A. fumigatus hyphae to several concentrations (1-16 mg/L) of voriconazole or amphotericin B for various time intervals killed the hyphae in a time- and drug concentration-dependent manner. Voriconazole at 1 mg/L killed >95% of the hyphae grown on Sabouraud dextrose agar after 48 h of exposure, whereas amphotericin B at the same concentration killed approximately 70% of the hyphae after exposure for the same duration. Approximately 99% killing of hyphae grown in peptone yeast extract glucose broth was obtained for voriconazole at 1 mg/L after 48 h of exposure, whereas amphotericin B at 1 mg/L yielded approximately 82% killing after 48 h. The fungal cell viability test by tetrazolium reduction assay showed that mycelia exposed to > or =1 mg/L (Sabouraud dextrose agar blocks) and > or =2 mg/L (broth cultures) of voriconazole for 48 h completely failed to reduce 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide. At low concentrations (1-2 mg/L) amphotericin B had no detectable effect on 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide reduction by drug-treated mycelia, whereas mycelia treated with 16 mg/L for 48 h showed approximately 50% inhibition of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide reduction compared with the control.
CONCLUSIONS: Voriconazole possesses excellent fungicidal activity against actively growing hyphae of A. fumigatus. A comparison of results with those obtained for the known fungicidal drug amphotericin B shows that, in peptone yeast extract glucose broth, voriconazole has superior fungicidal activity against A. fumigatus hyphae compared with that of amphotericin B.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824093     DOI: 10.1093/jac/dki100

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Emerging threat of triazole-resistant Aspergillus fumigatus.

Authors:  Jeffrey M Rybak; Jarrod R Fortwendel; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

2.  Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.

Authors:  Valentina Salas; F Javier Pastor; Enrique Calvo; Deanna A Sutton; Annette W Fothergill; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.

Authors:  J Cadranel; B Philippe; C Hennequin; A Bergeron; E Bergot; A Bourdin; V Cottin; T Jeanfaivre; C Godet; M Pineau; P Germaud
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-11       Impact factor: 3.267

4.  Comparative analysis of programmed cell death pathways in filamentous fungi.

Authors:  Natalie D Fedorova; Jonathan H Badger; Geoff D Robson; Jennifer R Wortman; William C Nierman
Journal:  BMC Genomics       Date:  2005-12-08       Impact factor: 3.969

5.  Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic-pharmacodynamic analysis of tear fluid following oral administration.

Authors:  Norihisa Tamura; Atsushi Okano; Taisuke Kuroda; Hidekazu Niwa; Kanichi Kusano; Yoshikazu Matsuda; Kentaro Fukuda; Hiroshi Mita; Shunichi Nagata
Journal:  Vet Ophthalmol       Date:  2020-05-08       Impact factor: 1.644

6.  Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during antifungal azole treatment.

Authors:  Sophie Henneberg; Anja Hasenberg; Andreas Maurer; Franziska Neumann; Lea Bornemann; Irene Gonzalez-Menendez; Andreas Kraus; Mike Hasenberg; Christopher R Thornton; Bernd J Pichler; Matthias Gunzer; Nicolas Beziere
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

7.  Use of the tetrazolium salt MTT to measure cell viability effects of the bacterial antagonist Lysobacter enzymogenes on the filamentous fungus Cryphonectria parasitica.

Authors:  Nrupali Patel; Peter V Oudemans; Bradley I Hillman; Donald Y Kobayashi
Journal:  Antonie Van Leeuwenhoek       Date:  2013-03-26       Impact factor: 2.271

8.  Comparison of echinocandin antifungals.

Authors:  Gregory Eschenauer; Daryl D Depestel; Peggy L Carver
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.